|
About Aradigm
Business Overview
 Leadership
|
Pioneering Advancements in the Pulmonary
Pharmaceutical Industry.
Aradigm's
team represents a rare combination of multidisciplinary expertise and has
experience bringing a variety of pharmaceutical and health care products to
market in the U.S.
and internationally. Members of the company's Scientific Advisory Board are
among the world's leading experts in pulmonary medicine. Together, this
leadership team is pioneering important advancements in the pulmonary
pharmaceutical industry and positioning Aradigm as a new leader in the
specialty pharmaceutical market.
Executive Management
|
|
|
Igor Gonda,
Ph.D.
President
& Chief Executive Officer
Dr. Gonda has served as President and Chief Executive
Officer since August 2006, and as a director since September
2001. From December 2001 to August 2006, Dr. Gonda was
the Chief Executive Officer and Managing Director of Acrux
Limited, a publicly traded specialty pharmaceutical company
located in Melbourne,
Australia.
From July 2001 to December 2001, Dr. Gonda was our Chief
Scientific Officer and, from October 1995 to July 2001,
was our Vice President, Research and Development. From
February 1992 to September 1995, Dr. Gonda was a Senior
Scientist and Group Leader at Genentech, Inc. leading
inhalation development of products for severe respiratory
disease. Prior to that, Dr. Gonda held academic positions
at the University
of Aston in Birmingham, United Kingdom,
and the University of Sydney, Australia. Dr. Gonda holds
a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry
from Leeds University,
United Kingdom.
Dr. Gonda was the Chairman of our Scientific Advisory
Board until August 2006. |
| |
|
|
|
|
|
Babatunde A. Otulana, M.D.
Senior
Vice President, Development, Chief Medical Officer
Dr. Otulana has served as our Senior Vice President, Development,
since August 2006. Prior to that, Dr. Otulana served as
our Vice President, Clinical and Regulatory Affairs since
October 1997. From 1991 to September 1997, Dr. Otulana
was a Medical Reviewer in the Division of Pulmonary Drug
Products at the Center for Drug Evaluation and Research
of the United States Food and Drug Administration. Dr.
Otulana currently serves as an Associate Clinical Professor
in Pulmonary Medicine at the School of Medicine,
University of
California at Davis. Dr. Otulana holds an M.D. from
the University of Ibadan, Nigeria, and completed Pulmonary
Fellowships at Papworth
Hospital, University
of Cambridge, United Kingdom, and at Howard University Hospital, Washington,
D.C. He has been responsible for conducting several dozens
of clinical trials. |
| |
|
|
|
|
|
Norm
Halleen
Interim Chief Financial Officer
Mr. Halleen served as Aradigm’s Vice President,
Finance and Chief Financial Officer from 1999 to 2001,
and has more than two decades of senior-level financial
and management experience, primarily in the healthcare
industry. Previously, he was Senior Vice President and
Chief Financial Officer for InterMune, Inc., a biopharmaceutical
company with annual revenues of approximately $150 million.
Prior to that, he was Vice President and Chief Financial
Officer for Syrrx, Inc., a drug discovery company. Mr.
Halleen holds a Bachelor of Arts degree from Stanford
University, and a Master of Business Administration from
Harvard Graduate School of Business.
|
| |
|
|
Board of Directors
Virgil D. Thompson
Chairman of the Board, Aradigm Corporation
President, Chief Executive Officer & Director,
Angstrom Pharmaceuticals, Inc.
Frank H. Barker
Former Group Chairman, Johnson & Johnson
Igor Gonda, Ph.D.
President & Chief Executive Officer, Aradigm Corporation
Stephen O. Jaeger
Chairman, Savient Pharmaceuticals, Inc.
Dr. John M. Siebert
Chairman & Chief Executive Officer, CyDex, Inc.;
Former CEO of CIMA Labs
Timothy P. Lynch
President and Chief Executive Officer of NeuroStat Pharmaceuticals
Scientific Advisory Board
Aradigm's Scientific Advisory Board is a highly regarded team of scientific
experts who help the Company with strategic input into the development of
treatments for severe respiratory disease, hormonal and metabolic
disorders, and in pharmaceutical development and pulmonary drug delivery in
general. The group assists the company on a variety of issues related to
potential product applications, product development paths and clinical
testing.
Peter R.
Byron,
Ph.D.
Medical College
of Virginia, Virginia Commonwealth
University. Area of
expertise: Aerosol Science/ Pharmaceutics
Peter S. Creticos, M.D.
The Johns Hopkins University School of Medicine
Area of expertise: Allergy/Immunology/Asthma
Stephen J. Farr, Ph.D.
Zogenix, Inc. Area of expertise: Pulmonary Delivery/Pharmaceutics
Phyllis Gardner, M.D.
Stanford University. Area of expertise: Clinical Pharmacology/Drug
Development
Michael Konstan,
M.D.
Rainbow Babies and Children’s Hospital. Area of expertise: Pulmonary
Disease/Cystic Fibrosis
Michael Powell, Ph.D.
Sofinnova Ventures. Area of expertise: Drug Development
Adam Wanner, M.D.
University of Miami. Area of expertise: Chronic
Obstructive Pulmonary Disease (COPD)
Martin Wasserman, Ph.D.
Roche, AtheroGenics (retired). Area of expertise: Asthma
In
addition to this Scientific Advisory Board, the company also engages other
scientific and medical experts to assist on issues specific to particular
indications and programs.
|
